
NavDx
Optimizing HPV+ Cancer Care



Routine Monitoring with the NavDx® Test

What is Routine Monitoring with the NavDx test?

Clinical practice guidelines[1] recommend that patients who have completed treatment for HPV+ head and neck or anal cancer receive regular monitoring (also called **surveillance testing**) for recurrent cancer. Better outcomes can be achieved for patients whose recurrent cancer is detected earlier according to clinical studies.

The NavDx test detects a specific cancer-associated biomarker called TTMV®-HPV DNA. A positive NavDx test result—indicating the presence of TTMV-HPV DNA fragments—may indicate that disease is present. Studies have shown that routine monitoring with the NavDx test can help detect recurrence earlier than the appearance of symptoms, radiologic imaging, or biopsies[2].

Routine monitoring with the NavDx test is simple, and the Naveris team strives to make it fit seamlessly into your life. As a patient, here's what you can expect to experience:

1



Provider orders a series of NavDx tests for the next 12 months.

The blood draw for the first test may take place in your physician's office, or Naveris can arrange for the blood draw to be completed at your home or at a local walk-in clinic.

2



Review the results with your provider.

Providers generally receive results within 7 business days, and they may discuss the results with you at your next follow-up appointment or sooner, at their discretion.


3



Let us help you stay on schedule.

As your next testing period approaches, Naveris may reach out to you to remind you to schedule your next blood draw.

4



Get your next blood draw.

Just like before, this can be done in your physician's office, at home or at a walk-in clinic, if using our Mobile Phlebotomy service.

Share this with your provider. It could be time for your next NavDx test.

A growing number of commercial insurance companies cover NavDx testing. Coverage varies based on insurance and service type. NavDx testing is a covered benefit for Medicare patients when monitoring for HPV+ anal or oropharyngeal cancer recurrence. Medicare covers four tests annually during OPSCC surveillance in the first two years post-treatment, and two tests annually thereafter, up to five years post-treatment. For ASCC surveillance, Medicare covers four tests annually in the first three years post-treatment, and two tests annually thereafter, up to five years post-treatment.

Learn more about NavDx testing.

The NavDx test was developed by and is only performed by Naveris using our certified and accredited clinical testing laboratories.

1. https://www.nccn.org/guidelines/. 2. Chera BS, Kumar S, Beaty BT, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. 2020. http://www.doi.org/10.1200/JCO.19.02444.

CareDx

© 2026 Naveris (now part of CareDx) 21 Hickory Drive, Suite 600, Waltham, MA 02451 | www.naveris.com | support@naveris.com
US Patents 11,254,989 and 11,168,373 | NavDx-1025-239R1.5